📋

GLP-1 & HRT: The Legal Money Model

Private brief. Enter password to continue.

That's not right. Try again.

Prepared for Pauli · Evolution Dermatology and Wellness

Adding GLP-1 and HRT: the legal way to make money on the medicines

Prepared by Annette Thompson

July 13, 2026

Pauli, here's the short version of the homework I promised. A dermatology practice like yours is actually well-positioned to add GLP-1 weight management and hormone therapy, because you already have the two things that make it legal: a supervising physician and real medical infrastructure. The trick is to build around the model that still works in 2026, not the one that just got shut down. Here's the map.

This is a business brief, not legal or medical advice. I'm not an attorney. Every dollar item below turns on Colorado rules that your medical director and a Colorado healthcare attorney need to confirm before you build. Colorado-admitted options are named at the end.

Two legal ways to make money on the meds

1. Bill the service, not the drug (the durable GLP-1 model)

Charge a monthly clinical program fee that bundles the visit, dosing management, labs, and injection teaching. That's payment for professional care, which is clean. The patient gets the actual drug as a branded prescription. The profit lives in the recurring program, not the molecule.

2. In-office dispensing with a markup (where Colorado allows it)

Many states let a practice register as a dispensing practitioner, buy at wholesale, and dispense directly at a retail price, keeping the spread. This is the real "provide the medicine and profit" lever. It works cleanly for compounded bioidentical hormones and, with thinner margins, for branded GLP-1. Colorado has its own dispensing and labeling rules, so this one needs local confirmation.

Where each line stands in 2026

GLP-1. The compounded-copy gold rush is over. The FDA resolved the semaglutide and tirzepatide shortages (Feb 2025 and late 2024) and in April 2026 moved to permanently bar them from bulk compounding. Enforcement is heavy. So the money is in the branded prescription plus the recurring program, plus the aftercare that weight loss creates (skin tightening, volume restoration, contouring), which is the higher-margin layer a derm practice is built to capture. Patient-specific 503A compounding survives only with a documented individual clinical need, never "it's cheaper."

HRT. The healthier line right now. Compounded bioidentical hormones are the fastest-growing segment in compounding, and the FDA removed old boxed warnings on certain hormone products in 2025. Custom doses, creams, troches, pellets, injectables. Pellet insertion is itself a billable procedure, so that's service revenue plus product revenue in one visit. Note testosterone is a Schedule III controlled substance, which adds DEA registration and stricter rules.

The one non-negotiable: the Good Faith Exam

Everything above only works if the very first step is done right, so this part is worth pulling out on its own.

Why the Good Faith Exam is non-negotiable

A prescription written without a real exam isn't a weak prescription. Legally, it's not a prescription at all.

That single rule is what turns "injecting off a signup form" into two separate crimes: unlicensed practice of medicine, and, for anything scheduled like testosterone, illegal distribution of a controlled substance. It is the floor every other decision in this brief sits on. The authority runs from a federal regulation up to a Supreme Court case:

21 CFR 1306.04(a) — a valid prescription must be for a legitimate medical purpose in the usual course of practice; an order that isn't "is not a prescription" under the law.
United States v. Moore, 423 U.S. 122 (1975) — the Supreme Court let a physician be criminally prosecuted precisely because he "gave inadequate physical examinations or none at all."
Ryan Haight Act, 21 U.S.C. 829(e) — controlled substances (testosterone) require at least one real medical evaluation before prescribing, with only narrow telehealth exceptions.
State enforcement — every US state requires a documented Good Faith Exam by a prescriber before injectables, GLP-1s, or hormones. A checkbox intake form is explicitly not one.

And here's the case that proves it

United States v. Done Global. In November 2025, a federal jury convicted the founder and clinical head of a telehealth company of unlawful distribution of controlled substances for writing prescriptions to people "without an examination," some on nothing more than a short questionnaire. It was DOJ's first criminal telehealth-prescribing conviction. The signup-form model isn't a gray area anymore. It is a secured conviction with prison time attached.

For you, practically: the intake form can collect history and consent, but you (as PA) or your supervising physician have to actually evaluate and document each patient before the first dose, in person or via a compliant telehealth exam.

The compliance floor, in one glance

Documented Good Faith Exam by a prescriber before the first dose, every new patient.
Physician oversight matched to Colorado PA scope and supervision rules.
If dispensing in-office: dispensing-practitioner registration, proper labeling, lot and expiry tracking, cold-chain storage, recordkeeping.
Testosterone: DEA registration and controlled-substance handling.
Compounded GLP-1 only patient-specific with documented clinical need; never bulk-stocked, never marketed as cheaper.
Cash-pay avoids most federal kickback exposure, but Colorado fee-splitting and self-referral rules still apply.

The two calls that de-risk the whole thing

Before building, confirm with the Colorado Medical Board and the Colorado State Board of Pharmacy, and have a Colorado healthcare attorney review the structure once. Colorado-admitted options: Rocky Mountain Healthcare Law (Boulder/Denver, works with PAs and physicians), E.C. Lewis, P.C. (Denver, med spas), and Peggy Kozal at Dickinson Wright (Denver, health-law regulatory). A one-time review of a few hundred to a couple thousand dollars protects the entire revenue line.

Happy to talk any of this through, or to help you model the numbers on either line whenever you want.

Warmly,
Annette

Sources: FDA compounding guidance and Federal Register notices (2025 to 2026); 21 CFR 1306.04; United States v. Moore, 423 U.S. 122 (1975); Ryan Haight Act (21 U.S.C. 829(e)); DOJ v. Done Global (N.D. Cal., conviction Nov 2025); state Good Faith Exam guidance. Business summary only, not legal or medical advice. Verify with Colorado counsel and your medical director.